The AI Rare & Genetic Disease Research Intelligence agent — variant to therapy to patient.
A scientific research agent (not a chatbot, not a diagnostic tool) that discovers, connects, analyses, challenges and synthesises rare & genetic disease knowledge from authorized literature, databases, datasets and enterprise tools — to help you understand what is known, what is unknown, what may be true, what has failed and what to test next.
Twelve deeply-connected knowledge domains spanning the research lifecycle.
Monogenic & polygenic rare disorders — inborn errors of metabolism, neuromuscular, lysosomal storage, mitochondrial, skeletal, immunologic and undiagnosed diseases across paediatric and adult onset.
Variant discovery & interpretation (ACMG), loss/gain-of-function, splicing, structural variants, penetrance, modifiers, mosaicism and genotype–phenotype correlations.
Whole-genome/exome, long-read sequencing, RNA & splicing, proteomics, metabolomics and functional genomics — connected variant → transcript → protein → pathway → phenotype.
Patient iPSCs & organoids, CRISPR cellular models, zebrafish, mouse & other in-vivo models and in-silico predictions — with translational strengths and limitations made explicit.
Human-genetic, functional and multi-omics evidence for rare-disease targets — with modality fit, delivery challenges, safety, prior programs and research gaps clearly separated.
Gene therapy (AAV), gene editing (CRISPR/base/prime), ASO & siRNA, enzyme replacement, small molecules, chaperones and repurposing — across the discovery-to-development cascade.
Diagnostic, prognostic and PD biomarkers, plus natural-history and registry evidence needed to design feasible trials in small, heterogeneous populations.
Small-population & N-of-1 designs, endpoints, biomarkers, comparators, results and adverse events — surfacing failed hypotheses, feasibility constraints and design opportunities.
Orphan-drug pathways, accelerated approval, surrogate endpoints and the evidence expectations that shape rare-disease development — described, never invented.
Variant prioritization, burden testing, phenotype clustering, survival & longitudinal modelling and multi-omics integration on authorized rare-disease datasets.
Reasons across Disease ↔ Gene ↔ Variant ↔ Transcript ↔ Protein ↔ Pathway ↔ Model ↔ Biomarker ↔ Target ↔ Modality ↔ Trial ↔ Outcome, with every claim traceable to primary sources.
Finds undiagnosed-disease leads, variants of uncertain significance, missing models & biomarkers and translational gaps — then frames testable hypotheses and experiments.
Surface novel, testable research directions and drug-repurposing leads across the whole ecosystem — not a single paper.
Integrate literature, omics, trials and real-world data into one traceable evidence graph so hidden connections become visible.
A built-in scientific critic tests for confounding, batch effects, power, publication bias, replication and prior failures.
Research questions, proposals, protocols, SAPs, reviews and manuscript scaffolds — never fabricating data, patients, stats or citations.
Statements are tagged so you always know their standing — and confidence is stated, never inflated. Citations, DOIs, PMIDs, dataset and trial IDs are drawn from primary sources; if a source can't be verified it says so. Rare Disease Genius is a research-intelligence system, not a substitute for a physician — it does not diagnose or treat individuals.
We use cookies to run Anxya Health and improve your experience. Choose how we may use them. Read our Cookie Policy, Privacy Policy and Terms.